Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors

JOURNAL OF CLINICAL ONCOLOGY(2022)

引用 1|浏览23
暂无评分
关键词
advanced methylthioadenosine phosphorylase,tumors,inhibitor,dose-escalation
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要